Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- TB Drug Deltyba Approved in Russia: Otsuka
May 26, 2020
- Tanabe Mitsubishi Gets Tenelia OK in Thailand
May 26, 2020
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Simon Lee to Lead ViiV Japan from June
May 26, 2020
- Sawai Ponders Possible Delay in Rollout of 4 Generic Brands After June Listing
May 26, 2020
- Takeda’s NSCLC Med Alunbrig Nabs Frontline Nod in US
May 26, 2020
- 90% of Drug Promotion Shifted to Remote Tools; Prudent Attitude Needed for New Launches amid COVID-19: IQVIA Official
May 25, 2020
- Enhertu Gets US FDA’s Orphan Status for Gastric Cancer
May 25, 2020
- US FDA Approves Sunovion’s Apomorphine Sublingual Film for Parkinson’s
May 25, 2020
- Bayer Files Japan NDA for Larotrectinib in NTRK-Positive Solid Tumors
May 25, 2020
- Daiichi Sankyo Launches PI for DS-6157 for GIST; 5th ADC Entered in Clinical Stage
May 25, 2020
- As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea
May 22, 2020
- GSK Japan Looking to Develop Otilimab for COVID-19; President Stresses Efforts on Vaccines, Disease Management Too
May 22, 2020
- No. of Ambulatory Patients Sags 6% in March amid COVID-19, Greater Drop in Special Alert Prefectures: Survey
May 22, 2020
- EMA Accepts Roxadustat for Review
May 22, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
- Zolgensma Hits Japan Market with Stringent Conditions Attached
May 21, 2020
- Nipro to Roll Out Symbicort Copy in June with Stable Supply System in Place
May 21, 2020
- Suzuken to Exclusively Distribute Novartis’ Zolgensma in Japan
May 21, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…